The Amateur Traders Corner Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Amateur Traders Corner

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Hua who wrote (4187)	12/12/2000 10:32:30 PM
From: DanWebzster	Read Replies (1) of 19633

I like RGEN here. It has a compound that received approvable status from FDA in April. Final approval is expected in January. If this compound (Secretin)is approved, it will likely generate significant revenue from off-label treatment of pediatric autism. Meanwhile RGEN has revenues from its protein for therapeutic antibody mfrng business and quite a bit of cash. It also has an early stage stem cell treatment. Looks ripe for end of year run. I just hope it's not another SNUS.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next